About the JPG
The Japanese Pharmaceutical Group (JPG) is an association of 11 life sciences companies of Japanese origin, namely Astellas, Chugai, Daiichi-Sankyo, Eisai, Kowa, Kyowa Kirin, Mitsubishi Tanabe, Otsuka, Santen, Shionogi, Sunovion and Takeda.
These member companies represent a diverse range of organisations, of varying size and footprint in the UK and include companies ranking in the top 10 globally. Turnover in the UK last year for the group as a whole, was in excess of £800 million.
Nine JPG members currently have their European headquarters in the UK, making their presence here important not just to the UK, but to the European region.
As a group the JPG employs approximately 2400 people in the UK, many of whom are highly skilled and educated graduates, working on therapeutic advances in a wide range of clinical areas.
JPG members conduct research and development, making significant investment both in terms of resource and advancement of clinical understanding and experience. Over £76 million was invested by JPG members directly in such development in the UK last year and significantly more within Europe as a whole.
JPG members are looking to bring innovation to the UK, with an impressive 40 new chemical entities (NCEs) hoping to be introduced in the next 5 years by the companies in the Group.
Therapeutic categories of products covered by JPG members include; anti-infectives (including new antibiotics), cardiovascular, diabetes, dermatology, endocrinology, gastroenterology, haematology, immunology, metabolism, mental health (schizophrenia), nephrology, neurology (e.g. ADHD, Alzheimer’s, epilepsy, multiple sclerosis), oncology, ophthalmology, pain, transplant, urology and vaccines.
Many of these innovations are in areas of high unmet medical need. Members are also increasingly looking at innovations in digital health, AI, gene therapy and the roles they can have in enhancing patient care and outcomes.